Business Context and Reporting Period
This Form 8-K is filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) on November 10, 2020. The filing serves to report the company's financial results for the three and nine months ended September 30, 2020, as detailed in a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific data regarding material changes versus prior comparable periods. It only confirms the issuance of results for the periods ended September 30, 2020.
Guidance, Outlook, and Risks
The filing text does not include management commentary, guidance, outlook, risks, contingencies, or unusual items. The document explicitly states that the press release containing these details is furnished but not "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the correct registrant name is Miragen Therapeutics, Inc. (Ticker: MGEN), as the request metadata incorrectly listed Viridian Therapeutics, Inc.
- Review Exhibit 99.1 (the press release dated November 10, 2020) for actual financial figures, as they are absent from the 8-K body text.
- Confirm the reporting periods covered are the three and nine months ended September 30, 2020.
- Note that the press release is furnished and not deemed "filed" under Section 18 of the Exchange Act.